Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New shoulder implant tracked for 10 years in 73 patients

NCT ID NCT03312465

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 26, 2026 · Updated 3 times

Summary

This study follows 73 people who received a shoulder replacement using the Anatomical Shoulder Domelock System. The goal is to see how well the device works and how safe it is over 10 years. Participants have conditions like arthritis or avascular necrosis and have not improved with other treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Anatomical Shoulder Domelock System (a shoulder replacement device)
What this could lead to
If successful, this could confirm that the device is a safe and effective option for shoulder replacement, helping to reduce pain and improve function.
What could go wrong
This is a post-market study with no control group, so results may not prove the device is better than other options. Some patients may experience complications like implant failure or need for revision surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

73 people

The number who actually took part.

Started

Sep 2017

Expected to finish

Dec 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients suffering from severe shoulder pain and disability indicated for implantation of the Anatomical Shoulder Domelock System in hemi or total shoulder arthroplasty and who meet all inclusion and none of the exclusion criteria.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient is 18-80 years of age, inclusive * Patient is skeletally mature * Patient is suffering from severe shoulder pain and disability requiring unilateral or bilateral HSA or TSA based on physical exam and medical history * Patient has failed conservative treatment * Patient meets at least one of the following indications: * Advanced wear and tear of the shoulder joint resulting from degenerative, posttraumatic or rheumatoid arthritis if bone stock is adequate. * Avascular necrosis * Conditions consequent to earlier operations * Optional use in revision: in some medical conditions (e.g., early revision when adequate bone stock exists), the surgeon may opt to use primary implants in a revision procedure. Additional criteria for retrospective patients: * patient has been implanted with the Domelock system before site initiation visit. * information available must include at minimum demographic information, the operative report and details of the device implanted. Exclusion Criteria: * Patient is unwilling or unable to give consent or to comply with the follow-up program * Patients who have any condition which would in the judgement of the Investigator place the patient at undue risk or interfere with the study. Any patient who is institutionalized, or is a known drug abuser, a known alcoholic or anyone who cannot understand what is required of them * Patient is known to be pregnant or breastfeeding * Patient meets at least one of the contraindications: * Patient's physical conditions that would impair adequate implant support and/or prevent the use of an appropriately sized implant, e.g., previous surgery, insufficient quality or quantity of bone, neuromuscular compromise or vascular deficiency in the affected limb in sufficient degree to endanger the success of the intervention e.g., absence of musculoligamentous supporting structures, joint neuropathy or other conditions that may lead to inadequate skeletal fixation * Signs of infection * Severe instability secondary to advanced loss of osteochondral structure * Charcot's shoulder (neuroarthropathy)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthritis rheumatoid are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • HELIOS ENDO-Klinik Hamburg

    Hamburg, Germany

  • Krankenhaus Maria Hilf

    Daun, Germany

  • Royal Derby Hospital

    Derby, DE22 3NE, United Kingdom

  • Univeritätklinik Bagrist

    Zurich, Canton of Zurich, 8008, Switzerland

  • Universitaire Ziekenhuizen Leuven

    Leuven, Belgium

  • Universitätsspital Basel

    Basel, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.